Physician profile
Shan Chu
NPI 1760477939
$5,611.65
in general payments reported to CMS, 2019-2025
25 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $174 · 2021: $672 · 2022: $904 · 2023: $639 · 2024: $771 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,498 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.72 |
| Education | $159.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,736.00 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,188.76 | 2019-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $652.05 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $337.90 | 2022-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $337.19 | 2019-2021 | |
| Electromed, INC. | $223.20 | 2023-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $222.67 | 2019-2022 | |
| Intuitive Surgical, INC. | $132.48 | 2023 | Da Vinci Surgical System |
| Genzyme Corporation | $130.41 | 2021-2025 | |
| Pulmonx Corporation | $103.60 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $99.26 | 2025 | Dupixent |
| Pfizer INC. | $78.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $59.80 | 2025 | |
| Mylan Specialty L.P. | $42.33 | 2021-2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $39.38 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $35.00 | 2019 | |
| Baxter Healthcare | $34.31 | 2022 | |
| Philips North America LLC | $24.96 | 2025 | Encore |
| Otsuka America Pharmaceutical, INC. | $24.91 | 2019 | |
| Insmed, INC. | $23.97 | 2023 | Arikayce |
| Shionogi INC | $20.96 | 2023 | Fetroja |
| Advanced Respiratory, INC | $16.57 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.39 | 2023 | Lifevest |
| Abbvie INC. | $16.31 | 2022 | |
| Amgen INC. | $14.57 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shan Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.